Regeneron Gets Long-Awaited FDA Okay for Myeloma Drug

U.S. FDA approves Regeneron's blood cancer therapy

Regeneron Pharmaceuticals gains FDA approval for Lynozyfic drug targeting multiple myeloma, with launch details and executive comments included.

Regeneron gets long-awaited FDA okay for myeloma drug

Regeneron's bid to join the crowded US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised

Advancing women’s health: Key updates and clinical insights from the first half of 2025

A look back at the most important FDA approvals, clinical research, and expert perspectives shaping ob-gyn care in the first half of 2025.

Regeneron nabs dosing edge with Lynozyfic's FDA approval in multiple myeloma - Pharmaceutical Technology

Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.

FDA Approves Linvoseltamab for Advanced Multiple Myeloma Treatment - BioPatrika

In a major breakthrough for blood cancer patients, the U.S. FDA has granted accelerated approval to linvoseltamab-gcpt (brand name Lynozyfic, developed by Regeneron Pharmaceuticals) — a powerful new therapy for relapsed or refractory multiple myeloma (MM). This approval offers fresh hope for patients who have exhausted at least four previous treatment options. 🧪 What is […] The post FDA Approves Linvoseltamab for Advanced Multiple Myeloma Treat…

FDA News Recap: Novel Drug Approvals in First Half of 2025

A review of the 16 novel drugs approved by the US Food and Drug Administration during the first half of 2025, with links to coverage from MJH Life Sciences publications.